Latest Research
All publications from the Cancer3.AI database, newest first.
Selenoproteins: Minute yet vital players governing cellular fate.
Xia C, et al
A new comprehensive review published in Genes & Diseases examines selenoproteins, a unique family of proteins that incorporate the rare amino acid selenocysteine and play essential roles in protecting cells from oxidative damage, regulating thyroid hormone metabolism, and determining cellular survival or death. The authors detail the complex molecular machinery required to produce and insert selenocysteine into these proteins, highlighting that this process is far more intricate than the synthesis of standard amino acids. A central focus of the review is the glutathione peroxidase (GPX) family, particularly GPX4, which has emerged as a key regulator of ferroptosis, a form of iron-dependent programmed cell death increasingly recognized as a target in cancer therapy. The review systematically maps the regulatory networks controlling selenoprotein function and catalogs how their dysfunction contributes to a range of diseases, including cancer. For patients and clinicians, this work is significant because it identifies selenoproteins as promising therapeutic targets, suggesting that drugs designed to modulate their activity could open new avenues for treating cancers that are resistant to conventional therapies.
Genes & diseases
Source →Monophasic Synovial Sarcoma in an Adolescent: A Great Mimicker of Benign Pathology.
Singh S, et al
A rare and diagnostically challenging soft-tissue cancer called monophasic synovial sarcoma was reported in a 13-year-old girl who presented with a painless, slowly growing lump in her upper leg over four months. Initial imaging suggested a benign nerve-sheath tumor known as a schwannoma, illustrating how this malignancy can convincingly mimic non-cancerous conditions. The tumor was surgically removed in its entirety, and laboratory analysis using histopathology and immunohistochemistry — including positive markers TLE1 and BCL2 — confirmed the diagnosis of monophasic synovial sarcoma. The patient subsequently received both chemotherapy and radiotherapy as part of a comprehensive treatment approach. This case underscores the critical need for clinicians to maintain a high level of suspicion for malignancy when evaluating deep-seated soft-tissue masses in young patients, even when imaging points toward a benign diagnosis. Early and accurate diagnosis combined with complete surgical excision and multimodal therapy remains essential to improving outcomes in synovial sarcoma.
Journal of Indian Association of Pediatric Surgeons
Source →Shaping the intestine: The role of cell morphology and spatial dynamics in development.
Wang Y, et al
This review examines how the small intestine develops its complex architecture from late embryogenesis through postnatal life, focusing on the cellular and molecular forces that shape its structure. Researchers analyzed the interplay between epithelial and mesenchymal cell signaling, the internal forces generated by the cytoskeleton, and external mechanical pressures that together drive the formation of the gut tube, smooth muscle layers, and the finger-like villi that dramatically increase nutrient absorption surface area. The study also details how crypts — the stem cell niches responsible for continual intestinal renewal — are formed and how epithelial cells migrate along the crypt-villus axis before being shed at the villus tip. Insights from animal models and laboratory-grown organoids reveal that the physical architecture of intestinal tissue both arises from and actively reinforces the maturation of specialized epithelial cells. Understanding these developmental processes is clinically relevant because disruptions to intestinal morphogenesis underlie conditions such as short bowel syndrome, inflammatory bowel disease, and congenital intestinal disorders, and could inform the design of better organoid-based therapies.
Current topics in developmental biology
Source →Histopathological and Clinical Features of HER2-Positive Breast Cancers across Hormone Receptor Subgroups: A Cross-Sectional Analysis.
Rao AC, et al
A new study published in F1000Research examined the clinical and histopathological characteristics of HER2-positive breast cancer across three hormone receptor subgroups, analyzing 117 patients treated at a tertiary care center over 42 months. Researchers compared triple-positive tumors (ER+/PR+/HER2+), ER-only positive tumors (ER+/PR-/HER2+), and HER2-enriched tumors (ER-/PR-/HER2+) using demographic, clinical, and pathological data. The HER2-enriched subgroup was found to occur in older patients (mean age 57.28 years) and was significantly associated with higher-grade tumors and more advanced lymph node involvement, suggesting a more aggressive biological behavior. Features such as lymphovascular invasion, tumor necrosis, and skin involvement did not differ significantly between the groups, while tumor size trended largest in the ER-only positive subgroup without reaching statistical significance. These findings highlight that HER2-positive breast cancer is not a uniform disease, and that hormone receptor status meaningfully shapes its clinical profile. Understanding these distinctions can help oncologists and pathologists refine prognosis and tailor individualized treatment strategies for patients with HER2-positive breast cancer.
F1000Research
Source →Prevention and Management of Peptide Receptor Radionuclide Therapy-Induced Hypertensive Crisis in a Patient With Metastatic Pheochromocytoma.
Yu R, et al
Researchers report a case study examining the prevention and management of life-threatening hypertensive crises triggered by peptide receptor radionuclide therapy (PRRT) with lutetium-177 DOTATATE in a 75-year-old man with metastatic pheochromocytoma, a rare tumor of the adrenal gland. The patient experienced dangerous spikes in blood pressure during the first, second, third, and fifth treatment cycles, even while on standard blood pressure medications known as alpha and beta blockers. Adding an extra dose of an alpha blocker immediately before treatment helped in some cycles but was not consistently effective at preventing the crises. Ultimately, a four-day course of metyrosine, a drug that reduces the production of catecholamines (stress hormones released by the tumor), taken before the sixth treatment successfully prevented the hypertensive crisis without requiring additional alpha blockade. The authors propose that PRRT may trigger these crises by directly stimulating catecholamine release from the tumor or by causing tumor cell destruction, and they recommend heightened caution in subsequent treatment cycles when a crisis has already occurred. This case highlights metyrosine as a valuable preventive strategy for clinicians managing PRRT in pheochromocytoma patients at high risk of hypertensive emergencies.
AACE endocrinology and diabetes
Source →